The cannabinoid receptor 1 gene (CNR1) and multiple sclerosis: an association study in two case-control groups from
E Ramil1, A J Sánchez, P González-Pérez
1Neuroinmunology Unit, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|December 17, 2009
Summary
Longer CNR1 gene variations, specifically AAT repeat lengths of 13 or more, may increase the risk for primary progressive multiple sclerosis (PPMS). This genetic marker was associated with PPMS in Spanish populations.
Area of Science:
- Neurogenetics
- Immunology
Background:
- The endocannabinoid system is implicated in multiple sclerosis (MS).
- The cannabinoid 1 (CB(1)) receptor, encoded by the CNR1 gene, is a key component of this system.
- Genetic variations in CNR1 may influence MS susceptibility or progression.
Purpose of the Study:
- To investigate the association between polymorphic markers at the CNR1 gene and MS.
- To analyze the role of AAT repeat microsatellites in the downstream region of CNR1 in Spanish MS patients and healthy controls.
Main Methods:
- Case-control genetic analysis of an AAT repeat microsatellite in the CNR1 gene.
- Study population included MS patients and healthy controls from Madrid and Bilbao, Spain.
- Statistical analysis to compare allele and genotype frequencies between groups.
Main Results:
- Longer AAT repeat alleles (≥13) and specific genotypes (e.g., 7/8) in the CNR1 gene were more common in primary progressive MS (PPMS) patients.
- A significant association was found for genotype 7/8 in Madrid and combined groups (p=0.043 and p=0.016, respectively).
- Shorter alleles, specifically allele 5, were less frequent in PPMS patients (p=0.039).
- No consistent differences were observed in relapsing MS patients.
- Disease severity and progression were not related to CNR1 AAT repeat variations.
Conclusions:
- Longer CNR1 genotypes (AAT ≥13) may represent a risk factor for developing PPMS.
- The findings suggest a potential genetic link between CNR1 variations and a specific MS subtype.
- Further research is warranted to confirm these genetic associations and explore underlying mechanisms.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...